We are helping shape the future of clinical trials by ensuring they are more diverse, inclusive and equitable. Our global Diversity, Equity and Inclusion in Clinical Trials (DEICT) team works to embed DEI at every stage of the clinical trial process.
Adding patients of color to our clinical trial enrollment enables our innovation teams to create medicines that specifically target those disproportionately affected by the disease. We created a framework to define recruitment targets for underrepresented groups in prospective clinical trials using real-world data, national demographics and historical trial recruitment. After analyzing the data, we created DEI goals for 18 studies in immunology, cardiovascular and oncology fields that were about to start or were in active recruitment.
Impact in 2023
At the end of 2023, 84% (31 of 37) actively recruiting studies were on track with their enrollment goals for diverse patients, as planned in their Diversity Action Plans. J&J was one of the first companies to submit Diversity Action Plans to the FDA, after draft guidance was published in 2022.
80%
of J&J clinical trials with diversity enrollment goals achieved their targets
26
diversity action plans across clinical trials in all therapeutic areas in trial proposals submitted to the FDA
